Quantifying the Arousal Threshold Using Polysomnography in Obstructive Sleep Apnea.
Scott A Sands, Philip I Terrill, Bradley A Edwards...
https://pubmed.ncbi.nlm.nih.gov/29228393/Actively Recruiting
Led by Brigham and Women's Hospital · Updated on 2026-09-21
24
Participants Needed
1
Research Sites
N/A
Total Duration
Obstructive sleep apnea OSA is a common disorder where the airway collapses repeatedly during sleep, causing poor sleep and low oxygen levels. Hypoglossal nerve stimulation HGNS is an approved treatment that uses a small implanted device to activate tongue muscles and keep the airway open. However, some patients still experience OSA despite HGNS. This research evaluates whether combining HGNS with the drugs atomoxetine and oxybutynin AtoOxy can better reduce breathing problems during sleep compared to either treatment alone. Participants with OSA who have an HGNS device implanted, or are scheduled for implantation, will take part in a randomized, placebo-controlled crossover trial. Each participant will receive four treatment periods in random order HGNS with AtoOxy, HGNS with placebo, AtoOxy alone HGNS off, and placebo alone HGNS off. The drug doses will start low and increase over the first three nights, and HGNS will be used at prescribed settings during sleep. During the study, participants will undergo polysomnographic sleep tests to measure breathing events and oxygen levels. They will also complete questionnaires on sleep quality, sleepiness, fatigue, and treatment satisfaction. Researchers will analyze how the combination treatment affects sleep breathing, explore why some patients respond better, and assess safety and patient experience. The total participation duration covers the four treatment periods and assessments over approximately two weeks each.
CONDITIONS
Combination Upper-Airway Electrical and Pharmacological Stimulation for Obstructive Sleep Apnea
D
Daniel P Vena, PhD
D
Dillon Gilbertson, BASc
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Brigham and Women's Hospital
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | HGNS + AtoOxy | HGNS alone | AtoOxy alone | Placebo | CPAP (standard care) |
|---|---|---|---|---|---|
| What it is | Combined unilateral hypoglossal nerve stimulation plus nightly atomoxetine‑oxybutynin oral dose | Unilateral hypoglossal nerve stimulation with placebo pills, device active | Atomoxetine‑oxybutynin oral therapy with HGNS device off | Matching placebo capsules and HGNS device off | Continuous positive airway pressure (CPAP) delivered nightly as standard first‑line OSA treatment |
| Role in trial | One of the four randomized crossover conditions evaluated | One of the four randomized crossover conditions evaluated | One of the four randomized crossover conditions evaluated | One of the four randomized crossover conditions evaluated | Not part of the trial; shown for clinical context only |
| Primary use | Investigational combined electrical and pharmacological intervention for OSA | Assess device‑only effect for OSA | Assess drug combination only for OSA | Control for placebo effect | First‑line, titratable therapy to maintain airway patency |
| How it is given or performed | HGNS device active during sleep plus nightly oral atomoxetine and oxybutynin, with dose escalation over first nights | HGNS device active during sleep plus matching placebo capsules at bedtime | Oral atomoxetine 80 mg and oxybutynin 5 mg at bedtime (initial half‑dose for 3 nights, then full dose); device off | Matching placebo capsules at bedtime; HGNS device off | Nightly positive airway pressure applied via mask, usually titrated to eliminate apnea events |
| Evidence status | Efficacy under investigation in this crossover trial; published crossover trial shows meaningful apnea reduction with AtoOxy alone | Device‑only efficacy established in prior studies of HGNS in CPAP‑intolerant OSA patients | AtoOxy showed significant apnea‑hypopnea index reduction over placebo in one crossover RCT | Placebo condition provides trial control for comparison | CPAP consistently reduces OSA severity, sleepiness, and blood pressure in moderate‑to‑severe cases |
| Important limitations | Efficacy and safety of combined device‑drug therapy not yet established | Effectiveness depends on patient selection; not suitable for all OSA patients | Single‑dose crossover data available; long‑term repeated dosing data limited | Represents no active intervention; not therapeutic | Effectiveness reduced by poor adherence in many patients |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened to determine if they meet the study's eligibility requirements.
1 visit (in-person)
Duration - Each period lasts approximately 2 weeks
Participants receive four different treatments in random order: HGNS combined with atomoxetine and oxybutynin, HGNS with placebo, atomoxetine and oxybutynin alone with HGNS off, and placebo alone with HGNS off. Each treatment period is followed by assessments.
Multiple visits during each treatment period
Duration - Up to study completion
Researchers analyze sleep test results and patient questionnaires to assess treatment effects and safety. Participants continue their usual medical care after the study.
Visits as needed for final evaluations
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
4
Have more questions? Get in touch with our team for quick support
Scott A Sands, Philip I Terrill, Bradley A Edwards...
https://pubmed.ncbi.nlm.nih.gov/29228393/Keri S Taylor, Hisayoshi Murai, Philip J Millar...
https://pubmed.ncbi.nlm.nih.gov/27698070/Justin C T Pepperell, Sharon Ramdassingh-Dow, Nicky Crosthwaite...
https://pubmed.ncbi.nlm.nih.gov/11812555/Justin C T Pepperell, Nick A Maskell, David R Jones...
https://pubmed.ncbi.nlm.nih.gov/12928310/David H Winslow, Charles H Bowden, Karen P DiDonato...
https://pubmed.ncbi.nlm.nih.gov/23115402/Craig L Phillips, Ronald R Grunstein, M Ali Darendeliler...
https://pubmed.ncbi.nlm.nih.gov/23413266/Philip I Terrill, Bradley A Edwards, Shamim Nemati...
https://pubmed.ncbi.nlm.nih.gov/25323235/C M Ryan, K Usui, J S Floras...
https://pubmed.ncbi.nlm.nih.gov/15994252/Bradley A Edwards, Scott A Sands, Danny J Eckert...
https://pubmed.ncbi.nlm.nih.gov/22219335/Ali Azarbarzin, Scott A Sands, Katie L Stone...
https://pubmed.ncbi.nlm.nih.gov/30376054/Brigham and Women's Hospital
Lead Sponsor